229 related articles for article (PubMed ID: 12096483)
1. [Thalidomide for the treatment of refractory multiple myeloma].
Kakimoto T; Hattori Y; Okamoto S
Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
[No Abstract] [Full Text] [Related]
2. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Go RS; Horstman AL
Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
[No Abstract] [Full Text] [Related]
3. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
4. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
5. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Pitini V; Arrigo C; Aloi G; Azzarello D; La Gattuta G
Haematologica; 2002 Feb; 87(2):ELT07. PubMed ID: 11836184
[No Abstract] [Full Text] [Related]
6. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
7. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
9. Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF.
Pittini V; Teti D; Arrigo C; Aloi G; Righi M
Br J Haematol; 2002 Oct; 119(1):275. PubMed ID: 12358938
[No Abstract] [Full Text] [Related]
10. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
[TBL] [Abstract][Full Text] [Related]
12. [Thalidomide and others: new treatment for myeloma].
Malphettes M; Fermand JP
Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
[No Abstract] [Full Text] [Related]
13. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G
Ann Oncol; 2001 Jul; 12(7):987-90. PubMed ID: 11521807
[TBL] [Abstract][Full Text] [Related]
14. Low-dose of thalidomide in the treatment of refractory myeloma.
Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
[No Abstract] [Full Text] [Related]
15. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in refractory and relapsing multiple myeloma.
Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
[TBL] [Abstract][Full Text] [Related]
18. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H
Br J Haematol; 2001 Dec; 115(3):605-8. PubMed ID: 11736942
[TBL] [Abstract][Full Text] [Related]
19. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
20. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
